CN1602850A - 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法 - Google Patents

一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法 Download PDF

Info

Publication number
CN1602850A
CN1602850A CN 200410070336 CN200410070336A CN1602850A CN 1602850 A CN1602850 A CN 1602850A CN 200410070336 CN200410070336 CN 200410070336 CN 200410070336 A CN200410070336 A CN 200410070336A CN 1602850 A CN1602850 A CN 1602850A
Authority
CN
China
Prior art keywords
alanyl
glutamine
charcoal
add
mannitol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200410070336
Other languages
English (en)
Other versions
CN100428931C (zh
Inventor
陶灵刚
陈胜龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ling Kang Pharmaceutical Group Ltd By Share Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB2004100703361A priority Critical patent/CN100428931C/zh
Publication of CN1602850A publication Critical patent/CN1602850A/zh
Application granted granted Critical
Publication of CN100428931C publication Critical patent/CN100428931C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供了一种注射用N(2)-L-丙氨酰-L-谷氨酰胺及其制备方法,本发明将N(2)-L-丙氨酰-L-谷氨酰胺和甘露醇混合制成重量百分比浓度为50~100%的注射用N(2)-L-丙氨酰-L-谷氨酰胺。本发明的注射用N(2)-L-丙氨酰-L-谷氨酰胺,极大提高了药物的稳定性,便于运输、贮藏;适用于需要补充谷氨酰胺的病人,包括处于分解代谢和高代谢状况的病人。

Description

一种注射用N(2)-L-丙氨酰-L-谷氨酰胺及其制备方法
                      技术领域
本发明涉及一种注射用N(2)-L-丙氨酰-L-谷氨酰胺及其制备方法。
                      背景技术
N(2)-L-丙氨酰-L-谷氨酰胺是肠外营养的一个组成部分,适用于需要补充谷氨酰氨的病人,包括处于分解代谢和高代谢状况的病人。
国内已上市的N(2)-L-丙氨酰-L-谷氨酰胺制剂为注射液,这种注射液不便于运输、贮藏。
                      发明内容
本发明提供了一种便于运输、贮藏的注射用N(2)-L-丙氨酰-L-谷氨酰胺及其制备方法。
本发明的注射用N(2)-L-丙氨酰-L-谷氨酰胺由N(2)-L-丙氨酰-L-谷氨酰胺和甘露醇组成,所含N(2)-L-丙氨酰-L-谷氨酰胺的重量百分比浓度为50~100%。
本发明的一种注射用N(2)-L-丙氨酰-L-谷氨酰胺的制备方法包括以下步骤:
将N(2)-L-丙氨酰-L-谷氨酰胺加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤后,分装于冻干托盘中,药液液面厚度不超过2cm;将制品经冷冻干燥或喷雾干燥后,得N(2)-L-丙氨酰-L-谷氨酰胺无菌粉未;
将甘露醇加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥或喷雾干燥后得甘露醇无菌粉末;
在百级洁净室中,将N(2)-L-丙氨酰-L-谷氨酰胺无菌粉未和甘露醇无菌粉末混合均匀,分装即得。
本发明的注射用N(2)-L-丙氨酰-L-谷氨酰胺,极大提高了药物的稳定性,便于运输、贮藏;本发明的注射用N(2)-L-丙氨酰-L-谷氨酰胺适用于需要补充谷氨酰胺的病人,包括处于分解代谢和高代谢状况的病人。
                    具体实施方式
实施例1
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
称取甘露醇50g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉10g和甘露醇无菌粉末10g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,10g/支。
实施例2:
称取80gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥得无菌粉末。
称取甘露醇80g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,经冷冻干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉20g和甘露醇无菌粉末20g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,20g/支。
实施例3:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
称取甘露醇50g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉10g和甘露醇无菌粉末5g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,10g/支。
实施例4:
称取60gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥得无菌粉末。
称取甘露醇60g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,经冷冻干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉20g和甘露醇无菌粉末10g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,20g/支。
实施例5:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
称取甘露醇50g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉10g和甘露醇无菌粉末1g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,10g/支。
实施例6:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥得无菌粉末。
称取甘露醇50g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,经冷冻干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉20g和甘露醇无菌粉末2g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,20g/支。
实施例7:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉10g,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,10g/支。
实施例8:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉20g,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,20g/支。
实施例9:
称取50gN(2)-L-丙氨酰-L-谷氨酰胺,加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
称取甘露醇50g加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,喷雾干燥得无菌粉末。
取上述N(2)-L-丙氨酰-L-谷氨酰胺无菌粉25g和甘露醇无菌粉末0.05g,混合均匀,在相对湿度55%以下,符合GMP要求的100级洁净区内分装,即得,10g/支。
本发明不限于以上所述的实施例。

Claims (2)

1、一种注射用N(2)-L-丙氨酰-L-谷氨酰胺,其特征在于由N(2)-L-丙氨酰-L-谷氨酰胺和甘露醇组成,所含N(2)-L-丙氨酰-L-谷氨酰胺的重量百分比浓度为50~100%。
2、根据权利要求1所述的一种注射用N(2)-L-丙氨酰-L-谷氨酰胺的制备方法,其特征在于包括以下步骤:
将N(2)-L-丙氨酰-L-谷氨酰胺加注射用水溶解,配制成20%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤后,分装于冻干托盘中,药液液面厚度不超过2cm;将制品经冷冻干燥或喷雾干燥后,得N(2)-L-丙氨酰-L-谷氨酰胺无菌粉未;
将甘露醇加注射用水溶解,配成10%的溶液,加入0.1%(w/v)的药用炭,吸附20分钟,粗滤脱炭;以φ0.22μm的微孔滤膜精滤,冷冻干燥或喷雾干燥后得甘露醇无菌粉末;
在百级洁净室中,将N(2)-L-丙氨酰-L-谷氨酰胺无菌粉未和甘露醇无菌粉末混合均匀,分装即得。
CNB2004100703361A 2004-08-02 2004-08-02 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法 Expired - Fee Related CN100428931C (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100703361A CN100428931C (zh) 2004-08-02 2004-08-02 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100703361A CN100428931C (zh) 2004-08-02 2004-08-02 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法

Publications (2)

Publication Number Publication Date
CN1602850A true CN1602850A (zh) 2005-04-06
CN100428931C CN100428931C (zh) 2008-10-29

Family

ID=34666794

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100703361A Expired - Fee Related CN100428931C (zh) 2004-08-02 2004-08-02 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法

Country Status (1)

Country Link
CN (1) CN100428931C (zh)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102228444A (zh) * 2011-04-13 2011-11-02 贵州益佰制药股份有限公司 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺制剂及其制备方法
CN102429902A (zh) * 2011-09-09 2012-05-02 海南灵康制药有限公司 一种丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN102631665A (zh) * 2012-04-19 2012-08-15 海南灵康制药有限公司 一种丙氨酰谷氨酰胺注射液和复方氨基酸注射液的药物组合物
CN102698248A (zh) * 2012-06-20 2012-10-03 海南灵康制药有限公司 一种喷雾干燥法制备的丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN103293236A (zh) * 2012-12-26 2013-09-11 辰欣药业股份有限公司 一种测定丙胺酰谷氨酰胺含量的方法
CN103508077A (zh) * 2012-06-25 2014-01-15 贵州益佰制药股份有限公司 一种药物包装系统及静脉给药的试剂盒
CN103610652A (zh) * 2013-11-27 2014-03-05 海南通用康力制药有限公司 一种丙氨酰谷氨酰胺冻干粉的制备方法
CN105125497A (zh) * 2015-09-20 2015-12-09 成都育芽科技有限公司 一种n(2)-l-丙氨酰-l-谷氨酰胺注射剂的制备方法
CN107281460A (zh) * 2017-05-25 2017-10-24 海南全星制药有限公司 一种注射用丙氨酰谷氨酰胺的制备方法

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102228444A (zh) * 2011-04-13 2011-11-02 贵州益佰制药股份有限公司 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺制剂及其制备方法
CN102429902A (zh) * 2011-09-09 2012-05-02 海南灵康制药有限公司 一种丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN102631665B (zh) * 2012-04-19 2013-09-25 海南灵康制药有限公司 一种丙氨酰谷氨酰胺注射液和复方氨基酸注射液的药物组合物
CN102631665A (zh) * 2012-04-19 2012-08-15 海南灵康制药有限公司 一种丙氨酰谷氨酰胺注射液和复方氨基酸注射液的药物组合物
CN102698248B (zh) * 2012-06-20 2013-09-25 海南灵康制药有限公司 一种喷雾干燥法制备的丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN102698248A (zh) * 2012-06-20 2012-10-03 海南灵康制药有限公司 一种喷雾干燥法制备的丙氨酰谷氨酰胺和复方氨基酸的药物组合物
CN103508077A (zh) * 2012-06-25 2014-01-15 贵州益佰制药股份有限公司 一种药物包装系统及静脉给药的试剂盒
CN103293236A (zh) * 2012-12-26 2013-09-11 辰欣药业股份有限公司 一种测定丙胺酰谷氨酰胺含量的方法
CN103610652A (zh) * 2013-11-27 2014-03-05 海南通用康力制药有限公司 一种丙氨酰谷氨酰胺冻干粉的制备方法
CN105125497A (zh) * 2015-09-20 2015-12-09 成都育芽科技有限公司 一种n(2)-l-丙氨酰-l-谷氨酰胺注射剂的制备方法
CN105125497B (zh) * 2015-09-20 2018-11-20 南京恩泰医药科技有限公司 一种n(2)-l-丙氨酰-l-谷氨酰胺注射剂的制备方法
CN107281460A (zh) * 2017-05-25 2017-10-24 海南全星制药有限公司 一种注射用丙氨酰谷氨酰胺的制备方法
CN107281460B (zh) * 2017-05-25 2018-05-18 海南全星制药有限公司 一种注射用丙氨酰谷氨酰胺的制备方法

Also Published As

Publication number Publication date
CN100428931C (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
CN1602850A (zh) 一种注射用n(2)-l-丙氨酰-l-谷氨酰胺及其制备方法
WO2021082761A1 (zh) 一种碳酸镧修饰的共热解污泥生物炭及其制备方法和应用
CN107803119B (zh) 一种复合膜层的制备方法以及利用其去除制药废水中残留四环素的方法
Esfahani et al. Comparing humic acid and protein fouling on polysulfone ultrafiltration membranes: Adsorption and reversibility
CN1213378A (zh) 从Grifola提取的抗肿瘤物质
US20230086236A1 (en) Bifunctional composite membrane and preparation method and use thereof, and method for removing plasticizer in liquor
WO1993025191A2 (fr) Microspheres en polymere bioresorbable, exemptes de tensioactif, leur preparation et leur application comme medicament
US10179321B2 (en) Method for removal of metals from aqueous solutions using bio adsorbents
CN109985609A (zh) 一种琥珀酰-β-环糊精修饰的PAN膜吸附材料及其制备方法
Tumlos et al. Results of the study of chemical-, vacuum drying-and plasma-pretreatment of coconut (Cocos nucifera) lumber sawdust for the adsorption of methyl red in water solution
CN1813684A (zh) 5-氟尿嘧啶/壳聚糖纳米载药微球的制备方法
CN1919444A (zh) 一种可生物降解聚酯磁性复合微球的制备方法
De Vietro et al. Introduction of basic functionalities on the surface of granular adsorbers by low pressure plasma processes
Widiastuti et al. Determination of tetracycline residues in dairy milk powder and fresh dairy milk by HPLC method
CN1309779C (zh) 一种生物可降解聚合物磁性复合纳米颗粒的制备方法
CN1839837A (zh) 尼可地尔冻干粉的制备方法
CN1459284A (zh) 注射用新鱼腥草素钠冻干粉针剂及其制备方法
CN1233737C (zh) 聚乳酸自修饰羟基磷灰石/聚乳酸复合材料及制备方法
CN1839822A (zh) 一种含活性成分水飞蓟宾及其盐经注射给药的稳定的药物组合物
CN1857741A (zh) 血液或血液成分病原体灭活剂组合物及其配制方法
Chen et al. Study on the absorption effect of hydrolyzed hoof horn powder on cadmium ions
CN1615867A (zh) 注射用盐酸纳洛酮冻干粉针制剂
CN1762574A (zh) 合成高分子与活性炭杂化多孔微球及其制备方法和用途
CN1193790C (zh) 胸腺肽组合物注射剂及其制备方法
CN1868872A (zh) 空气净化活性竹炭

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Assignee: Hainan Lingkang Pharmaceutical Co., Ltd.

Assignor: Tao Linggang

Contract fulfillment period: 2009.6.1 to 2019.5.31 contract change

Contract record no.: 2009460000004

Denomination of invention: N (2) -L- -L- glutamine for injection and preparation method thereof

Granted publication date: 20081029

License type: Exclusive license

Record date: 2009.6.8

LIC Patent licence contract for exploitation submitted for record

Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.6.1 TO 2019.5.31; CHANGE OF CONTRACT

Name of requester: HAINAN PROV LINGKANG PHARMACEUTICAL CO., LTD.

Effective date: 20090608

ASS Succession or assignment of patent right

Owner name: HAINAN RUIJI PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: YAO LINGGANG

Effective date: 20101214

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 570125 ROOM 2601, XINDA BUSINESS BUILDING, NO.48, GUOMAO AVENUE, HAIKOU CITY, HAINAN PROVINCE TO: 570000 ROOM 415, YUKE BUILDING, KEJI AVENUE, NATIONAL HIGH-TECH ZONE, HAIKOU CITY, HAINAN PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20101214

Address after: 570000 room 415, Yu Cheng Building, science and technology Avenue, national hi tech Zone, Haikou, Hainan

Patentee after: Hainan Ruiji Pharmaceutical Co., Ltd.

Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601

Patentee before: Tao Linggang

DD01 Delivery of document by public notice

Addressee: Hainan Ruiji Pharmaceutical Co., Ltd.

Document name: Notification of Passing Examination on Formalities

ASS Succession or assignment of patent right

Owner name: HAINAN LINGKANG PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: HAINAN RUIJI PHARMACEUTICAL CO., LTD.

Effective date: 20120605

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 570000 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20120605

Address after: 570216 No. 8 workshop, Haikou Free Trade Zone, Hainan

Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd.

Address before: 570000 room 415, Yu Cheng Building, science and technology Avenue, national hi tech Zone, Haikou, Hainan

Patentee before: Hainan Ruiji Pharmaceutical Co., Ltd.

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130806

Address after: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building

Patentee after: Hainan Lingkang Pharmaceutical Co., Ltd.

Address before: 570216 No. 8 workshop, Haikou Free Trade Zone, Hainan

Patentee before: Hainan Lingkang Pharmaceutical Co., Ltd.

ASS Succession or assignment of patent right

Owner name: HAINAN LIONCO PHARMACEUTICAL GROUP CO., LTD.

Free format text: FORMER OWNER: HAINAN LINGKANG PHARMACEUTICAL CO., LTD.

Effective date: 20130930

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130930

Address after: 570216 No. 8 factory building, Haikou Free Trade Zone, Hainan

Patentee after: Hainan Ling Kang Pharmaceutical Group Limited by Share Ltd

Address before: 570216 Hainan Province, Haikou city Jinpan Industrial Development Zone Industrial Village No. 3-6 building

Patentee before: Hainan Lingkang Pharmaceutical Co., Ltd.

ASS Succession or assignment of patent right

Owner name: LIONCO PHARMACEUTICAL GROU CO., LTD.

Free format text: FORMER OWNER: HAINAN LIONCO PHARMACEUTICAL GROUP CO., LTD.

Effective date: 20140619

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 570216 HAIKOU, HAINAN PROVINCE TO: 856100 LHOKA PREFECTURE, TIBET AUTONOMOUS REGION

TR01 Transfer of patent right

Effective date of registration: 20140619

Address after: Naidong Zetang County of Tibet autonomous region in 856100 Prefecture is Naidong County Road No. 68 building second building a layer of

Patentee after: Ling Kang Pharmaceutical Group Limited by Share Ltd

Address before: 570216 No. 8 factory building, Haikou Free Trade Zone, Hainan

Patentee before: Hainan Ling Kang Pharmaceutical Group Limited by Share Ltd

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081029

Termination date: 20160802

CF01 Termination of patent right due to non-payment of annual fee